Cord Blood Registry, Inc. Report issue

For profit Phase 1 Phase 2
Founded: South San Francisco CA United States (1992)
Status: Acquired by AMAG Pharmaceuticals, Inc. (2015) → now Advanz Pharma (2015)

Organization Overview

First Clinical Trial
2011
NCT01343394
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CBR Systems, Inc. | Cord Blood Registry

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 2)

Cerebral Palsy (Phase 2)

Deafness (Phase 2)

Hearing Loss (Phase 2)

Hearing Loss, Sensorineural (Phase 2)

Ischemia (Phase 2)

Paralysis (Phase 2)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 3